title: Intravenous immunoglobulin for hemophagocytic lymphohistiocytosis?
authors.forename: Urban
authors.initials: U
authors.lastname: Emmenegger
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Spaeth
authors.forename: Klaus A
authors.initials: KA
authors.lastname: Neftel
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002648:Child; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D020031:Epstein-Barr Virus Infections / Q000150:complications; D005047:Etoposide / Q000008:administration & dosage; D015616:Histiocytosis, Non-Langerhans-Cell / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008262:Macrophage Activation / Q000187:drug effects*; D018579:Patient Selection; D015203:Reproducibility of Results
chemical_list: D000970:Antineoplastic Agents; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D005047:Etoposide; D016572:Cyclosporine